Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response

por Thoms, J W, Dal Pra, A, Anborgh, P H, Christensen, E, Fleshner, N, Menard, C, Chadwick, K, Milosevic, M, Catton, C, Pintilie, M, Chambers, A F, Bristow, R G
Publicado 2012

Pre-treatment neutrophil-to-lymphocyte ratio as predictor of adverse outcomes in patients undergoing radical cystectomy for urothelial carcinoma of the bladder

por Hermanns, T, Bhindi, B, Wei, Y, Yu, J, Noon, A P, Richard, P O, Bhatt, J R, Almatar, A, Jewett, M A S, Fleshner, N E, Zlotta, A R, Templeton, A J, Kulkarni, G S
Publicado 2014

An online Sexual Health and Rehabilitation eClinic (TrueNTH SHAReClinic) for prostate cancer patients: a feasibility study

por Matthew, A. G., Trachtenberg, L. J., Yang, Z. G., Robinson, J., Petrella, A., McLeod, D., Walker, L., Wassersug, R., Elliott, S., Ellis, J., Jamnicky, L., Fleshner, N., Finelli, A., Singal, R., Brock, G., Jarvi, K., Bender, J., Elterman, D.
Publicado 2021